SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 clinical trial results for their Duchenne Muscular Dystrophy treatment, potentially reversing a previous FDA rejection. The stock is currently halted, but the community is celebrating the news and anticipating a significant short squeeze, while also discussing buyout possibilities and criticizing those who doubted the company.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to reports of lowered AI software sales quotas, sparking concerns about AI leadership and competition from Google. The community is debating the impact on MSFT's AI strategy and its broader influence on the market, especially in relation to AI hardware players like NVDA. Some investors view this as a buying opportunity, while others express disappointment and question the company's current direction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss its recent price movements and potential involvement in acquiring Warner Bros. Discovery assets. Community members are weighing the potential impact of a WBD deal, as well as recent reports of Netflix lobbying for regulatory approval, with some suggesting that the stock is being manipulated.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to a major government contract win for an autonomous border-protection drone system, sparking significant community excitement. Investors are actively discussing the potential impact of this contract on future growth, the company's position in the defense sector, and possible short squeezes. The contract news has reinforced optimism about Ondas's long-term prospects.

$SMOL is the first memecoin with a verified OnlyFans launched on Solana via pump.fun. It follows Smol, a rescued Alabama dachshund who survived hoarding, shelter hunger, and a 5-day post-spay escape before finding her forever home. Now pampered with treats and spa days, she shares wholesome content—no adult themes, just derpy faces, snack videos, and rescue love. $SMOL aims to normalize kindness and support animal welfare through the creator economy.

Smol Fans

$SMOL is trending as community members rally around its unique narrative: a rescue dog on OnlyFans supporting other rescue animals. With comparisons to early-stage $DOGE and a focus on community-driven growth, $SMOL is gaining attention as a potential leader in the memecoin space on the Solana network. The coin's organic growth and the team's dedication are key talking points driving interest.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential implications of Marvell's acquisition of Celestial AI, a key POET customer, and the validation it provides for POET's photonic interposer technology. The community is speculating about increased demand for POET's products and potential acquisition by a larger player like Marvell or Broadcom, with some emphasizing the company's unique technology and strong cash position. Concerns remain around dilution and the company's ability to scale production.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a surge in data center demand, a Q3 earnings beat, and forward guidance exceeding expectations. The acquisition of Celestial AI for its interconnect technology is also fueling excitement, with the community discussing the strategic implications of vertical integration and potential synergies. However, some investors are wary of a potential overvaluation and are closely watching for a pullback.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing volatility as traders react to news of potential shifts in economic policy and the unwinding of certain trades. Community members are debating the implications of job data and potential interest rate cuts, while some express concerns about an AI bubble. Overall, the conversation revolves around uncertainty and potential market corrections amid existing economic conditions.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards as investors react to news of a large share offering intended to fund the repurchase of convertible notes, with some fearing dilution. The community is debating the long-term implications of this financial move, with opinions divided on whether it's a strategic maneuver or a sign of balance sheet strain. Adding to the volatility, commentary from Jim Cramer on CNBC has further fueled debate and speculation around the stock's future.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene ($CLNN) is trending due to positive ALS biomarker data for its CNM-Au8 drug candidate, showing statistically significant reductions in NfL and GFAP. The community is discussing the potential for accelerated FDA approval and a possible near-term valuation surge, while some traders point out short positions and warrant conversions. Overall, the conversation highlights optimism surrounding the drug's potential impact on ALS treatment and Clene's future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deutsche Bank AG Buys 7,282 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Deutsche Bank AG raised its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report) by 16.4% during the third quarter, according to its most recent disclosure with the...

Bristol Myers completes acquisition of Karuna Therapeutics

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Q1 2024 EPS Estimates for Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reduced by Zacks Research

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report)  Zacks Research decreased their Q1 2024 earnings estimates for shares of Karuna Therapeutics in a research report issued to...

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Given Consensus Rating of "Hold" by Analysts

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report) has been given an average recommendation of Hold by the sixteen research firms that are currently covering the stock...

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives Average Recommendation of "Hold" from Brokerages

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report) have received a consensus recommendation of Hold from the sixteen brokerages that are currently covering the...

Karuna Therapeutics, Inc. Expected to Earn FY2026 Earnings of ($4.32) Per Share (NASDAQ:KRTX)

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report)  Stock analysts at Zacks Research issued their FY2026 earnings estimates for shares of Karuna Therapeutics in a research report...

When Will Karuna Therapeutics, Inc. (NASDAQ:KRTX) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Karuna Therapeutics...

Karuna Therapeutics (KRTX, $329.71) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 14, 2024

This is a Bullish indicator signaling KRTX's price could rise from here. Traders may explore going long the stock or buying call options...

Karuna Therapeutics (KRTX, $329.71) RSI Indicator left the overbought zone on March 14, 2024

This is a signal that KRTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires

Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires...

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics isÂ advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

KRTX
Karuna Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KRTX News

KRTXKaruna Therapeutics Inc